Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib vs Docetaxel in Japanese NSCLC (V-15-32)
NCT00252707Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Sep 2003; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00252707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252707.